Eiger BioPharmaceuticals, Inc.
EIGRQOTCHealthcare
$8.50
+$0.50(+6.25%)
Market Cap$12586800
P/E Ratio—
52W High$16.0
52W Low$1.1
Eiger BioPharmaceuticals, Inc. (EIGRQ) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EIGRQ · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $15.77M | $13.48M | $12.14M | $0.00M | $0.00M |
| Cost of Revenue | $0.77M | $2.68M | $1.54M | $0.65M | $0.49M |
| Gross Profit | $15.00M | $10.80M | $10.60M | ($0.65M) | ($0.49M) |
| Gross Margin %(computed) | 95.09% | 80.13% | 87.28% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $62.33M | $75.28M | $64.44M | $41.59M | $51.79M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $20.56M | $17.11M |
| Total Operating Expenses | $86.78M | $103.55M | $87.54M | $61.50M | $68.42M |
| Operating Income | ($71.79M) | ($92.74M) | ($76.94M) | ($62.15M) | ($68.90M) |
| Operating Margin %(computed) | -455.12% | -687.78% | -633.66% | — | — |
| Interest Income | $2.21M | $1.08M | $0.16M | $0.70M | $0.00M |
| Interest Expense | $5.47M | $4.13M | $3.56M | $3.59M | $0.00M |
| Income Before Tax | ($74.96M) | ($96.75M) | ($33.85M) | ($65.05M) | ($70.25M) |
| Income Tax Expense | $0.01M | $0.02M | $0.06M | $0.00M | $0.00M |
| Net Income | ($74.96M) | ($96.78M) | ($33.92M) | ($65.05M) | ($70.25M) |
| Net Margin %(computed) | -475.26% | -717.71% | -279.34% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-50.78 | $-69.74 | $-29.98 | $-69.34 | $-92.50 |
| Wtd Avg Shares | 1.48M | 1.39M | 1.13M | 0.94M | 0.76M |
| EBITDA | ($68.74M) | ($91.90M) | ($29.50M) | ($61.50M) | ($68.42M) |
| EBITDA Margin %(computed) | -435.81% | -681.53% | -242.92% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Eiger BioPharmaceuticals, Inc. data
About Eiger BioPharmaceuticals, Inc. (EIGRQ) Income Statement
Eiger BioPharmaceuticals, Inc. (EIGRQ) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, EIGRQ reported revenue of $0.02B, gross profit of $0.01B (gross margin 95.09%), and net income of ($0.07B) — a net profit margin of -475.26%.
Frequently asked questions
EIGRQ · 4 questionsEiger BioPharmaceuticals, Inc. (EIGRQ) reported revenue of $0.02B for 2023, up 17.0% year-over-year.
EIGRQ revenueEIGRQ salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09